دورية أكاديمية
أعرض في EDS

Thrombocytopenia and disease outcomes in a cohort of patients with systemic lupus erythematosus. A post hoc analysis of the COMOSLE-EGYPT study.

التفاصيل البيبلوغرافية
العنوان: Thrombocytopenia and disease outcomes in a cohort of patients with systemic lupus erythematosus. A post hoc analysis of the COMOSLE-EGYPT study.
المؤلفون: Mohamed SS; Rheumatology Department, Cairo University, Cairo, Egypt., Gamal SM; Rheumatology Department, Cairo University, Cairo, Egypt., Mokbel A; Rheumatology Department, Cairo University, Cairo, Egypt., Alkamary AK; Internal Medicine Department, Cairo University, Cairo, Egypt., Siam I; Internal Medicine Department, National Research Center, Giza, Egypt., Soliman A; Dermatology Department, National Research Center, Giza, Egypt., Elgengehy FT; Rheumatology Department, Cairo University, Cairo, Egypt.
المصدر: International journal of rheumatic diseases [Int J Rheum Dis] 2024 Jan; Vol. 27 (1), pp. e15016. Date of Electronic Publication: 2024 Jan 10.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley on behalf of the Asia Pacific League of Associations for Rheumatology Country of Publication: England NLM ID: 101474930 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1756-185X (Electronic) Linking ISSN: 17561841 NLM ISO Abbreviation: Int J Rheum Dis Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Oxford, UK] : Wiley on behalf of the Asia Pacific League of Associations for Rheumatology
مواضيع طبية MeSH: Lupus Erythematosus, Systemic*/diagnosis , Lupus Erythematosus, Systemic*/drug therapy , Lupus Erythematosus, Systemic*/epidemiology , Thrombocytopenia*/diagnosis , Thrombocytopenia*/epidemiology, Humans ; Male ; Egypt/epidemiology ; Antibodies, Antiphospholipid ; Risk Factors
مستخلص: Background: Thrombocytopenia ranges from 20% to 40% in patients with systemic lupus erythematosus (SLE). It is usually associated with severe disease manifestations and worse disease outcomes.
Aim of the Study: To identify the frequency of thrombocytopenia in a cohort of Egyptian patients with SLE and to examine the relationship of thrombocytopenia with various disease manifestations and disease outcomes.
Methods: Data on 902 SLE patients were collected, including demographics, clinical, laboratory, immunological findings, and medications. SLE Disease Activity Index (SLEDAI) at baseline, last visit, and Systemic Lupus International Collaborating Clinics/ACR Damage Index (SLICC) were calculated. A comparison was done between patients with thrombocytopenia (group I) and patients without (group II) regarding different disease parameters. Regression analysis was done to examine if thrombocytopenia is a predictor of worse disease outcomes.
Results: Thrombocytopenia was found in 33% of our cohort. Longer disease duration was observed in group I compared to group II (p value = .01). As regards clinical manifestations, significantly higher frequencies of constitutional manifestations, anemia, arterial thrombosis, pulmonary hypertension, cardiac manifestations, neurological manifestations, gastrointestinal tract (GIT), and hepatic manifestations were detected in group I compared to group II. The disease damage index was detected to be significantly higher in group I as compared to group II (p value < .001). Mortality was higher in group I (p value < .001). Although it was found that antiphospholipid antibodies (APL) were associated with thrombocytopenia and their presence resulted in higher damage (p value: .001), the presence of thrombocytopenia even in patients with negative APL antibodies was associated with higher damage and mortality. Apart from thrombocytopenia, the male gender was also found to be an independent risk factor for mortality.
Conclusion: Thrombocytopenia was associated with more organ damage and higher mortality in SLE patients with or without APL antibodies. SLE patients with thrombocytopenia have a 3.4 times higher risk of mortality than patients without thrombocytopenia. Apart from thrombocytopenia, the male gender was also found to be an independent risk factor for mortality.
(© 2024 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.)
References: Galanopoulos N, Christoforidou A, Bezirgiannidou Z. Lupus thrombocytopenia: pathogenesis and therapeutic implications. Mediterr J Rheumatol. 2017;28(1):20-26. doi:10.31138/mjr.28.1.20.
Maitra S, Roy S, Mukherjee A, Naramala S, Bose S. Thrombocytopenia: a diagnostic dilemma and incidental detection of systemic lupus erythematosus in a middle-aged Asian male. Cureus. 2020;12(9):e10375. doi:10.7759/cureus.10375.
Zhao H, Li S, Yang R. Thrombocytopenia in patients with systemic lupus erythematosus: significant in the clinical implication and prognosis. Platelets. 2010;21:380-385.
Mok CC, Lee KW, Ho CT, Lau CS, Wong RW. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford). 2000;39:399-406. doi:10.1093/rheumatology/39.4.399.
Miller MH, Urowitz MB, Gladman DD. The significance of thrombocytopenia in systemic lupus erythematosus. Arthritis Rheum. 1983;26:1181-1186.
Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368:1033-1044. doi:10.1056/NEJMra1112830.
Fernández M, Alarcón GS, Apte M, et al. Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor. Arthritis Rheum. 2007;56:614-621.
Jallouli M, Frigui M, Marzouk S, et al. Clinical implications and prognostic significance of thrombocytopenia in Tunisian patients with systemic lupus erythematosus. Lupus. 2012;21:682-687.
Reveille JD, Bartolucci A, Alarcon GS. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum. 1990;33:37-48.
Ward MM, Pyun E, Studenski S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med. 1996;156:1337-1344.
Patel N, Mody GM. Acute presentation of thrombocytopenia in systemic lupus erythematosus is associated with a high mortality in South Africa. Lupus. 2014;23:204-212.
Fayyaz A, Igoe A, Kurien BT, et al. Haematological manifestations of lupus. Lupus Sci Med. 2015;2(1):e000078.
Gamal SM, Mokbel A, Niazy MH, et al. Comorbidities among Egyptian systemic lupus erythematosus: the COMOSLE-Egypt study. Chronic Illn. 2022;19:791-803. doi:10.1177/17423953221138921.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum. 1992;35(6):630-640.
Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363-369.
Chen Z, Zhong H, Dong G. Thrombocytopenia as a prognostic marker for systemic lupus erythematosus: a systematic review and meta-analysis. Am J Med Sci. 2019;357:461-467.
Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82:299-308.
González-Naranjo LA, Betancur OM, Alarcón GS, et al. Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: data from a multiethnic Latin American cohort. Semin Arthritis Rheum. 2016;45:675-683.
Keeling DM, Isenberg DA. Haematological manifestations of systemic lupus erythematosus. Blood Rev. 1993;7:199-207.
Gamal S, Mohamed S, Moghazy A. Thrombocytopenia in a cohort of primary and secondary antiphospholipid syndrome patients: relation to clinical, laboratory manifestations and damage index. Arch Rheumatol. 2022;37(2):252-260.
Krause I, Blank M, Fraser A, et al. The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome. Immunobiology. 2005;210:749-754.
Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019-1027.
Pontara E, Banzato A, Bison E, et al. Thrombocytopenia in high-risk patients with antiphospholipid syndrome. J Thromb Haemost. 2018;16:529-532.
Jiang N, Li M, Zhang M, et al. Chinese SLE treatment and research group (CSTAR) registry: clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus. PLoS One. 2019;14(11):e0225516. doi:10.1371/journal.pone.0225516.
Jung JH, Soh MS, Ahn YH, et al. Thrombocytopenia in systemic lupus erythematosus: clinical manifestations, treatment, and prognosis in 230 patients. Medicine (Baltimore). 2016;95(6):e2818. doi:10.1097/MD.0000000000002818.
Kokori SI, Ioannidis JP, Voulgarelis M, Tzioufas AG, Moutsopoulos HM. Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. Am J Med. 2000;108(3):198-204. doi:10.1016/s0002-9343(99)00413-1.
Artım-Esen B, Çene E, Şahinkaya Y, et al. Autoimmune haemolytic anaemia and thrombocytopaenia in a single-centre cohort of patients with systemic lupus erythematosus from Turkey: clinical associations and effect on disease damage and survival. Lupus. 2019;28(12):1480-1487. doi:10.1177/0961203319877245.
Miranda-Hernández D, Cruz-Reyes C, Monsebaiz-Mora C, et al. Active haematological manifestations of systemic lupus erythematosus lupus are associated with a high rate of in-hospital mortality. Lupus. 2017;26:640-645.
Ziakas PD, Giannouli S, Zintzaras E, Tzioufas AG, Voulgarelis M. Lupus thrombocytopenia: clinical implications and prognostic significance. Ann Rheum Dis. 2005;64:1366-1369.
Sultan SM, Begum S, Isenberg DA. Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. Rheumatology. 2003;42:230-234.
Harris EN, Asherson RA, Gharavi AE, Morgan SH, Derue G, Hughes GR. Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibody. Br J Haematol. 1985;59(2):227-230. doi:10.1111/j.1365-2141.1985.tb02988.x.
Atsumi T, Furukawa S, Amengual O, Koike T. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus. 2005;14(7):499-504.
Pons-Estel GJ, Andreoli L, Scanzi F, Cervera R, Tincani A. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun. 2017;76:10-20.
فهرسة مساهمة: Keywords: SLE; damage; mortality; thrombocytopenia
المشرفين على المادة: 0 (Antibodies, Antiphospholipid)
تواريخ الأحداث: Date Created: 20240111 Date Completed: 20240131 Latest Revision: 20240131
رمز التحديث: 20240131
DOI: 10.1111/1756-185X.15016
PMID: 38200649
قاعدة البيانات: MEDLINE
الوصف
تدمد:1756-185X
DOI:10.1111/1756-185X.15016